Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the sale of convertible bonds to new investors Shibuya Corp. and Shinsei Group and undisclosed existing investors.

Promethera believes combining its liver cell-based therapies with Baliopharm's humanized mAb atrosimab could offer an improved treatment option for patients with non-alcoholic steatohepatitis (NASH). Atrosimab is a tumor necrosis factor receptor 1 (TNFR1) antagonist in preclinical testing for NASH...